IL318658A - Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification - Google Patents
Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcificationInfo
- Publication number
- IL318658A IL318658A IL318658A IL31865825A IL318658A IL 318658 A IL318658 A IL 318658A IL 318658 A IL318658 A IL 318658A IL 31865825 A IL31865825 A IL 31865825A IL 318658 A IL318658 A IL 318658A
- Authority
- IL
- Israel
- Prior art keywords
- progression
- inhibition
- prevention
- treatment
- derivative compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22382738 | 2022-07-29 | ||
| PCT/EP2023/071128 WO2024023359A1 (en) | 2022-07-29 | 2023-07-31 | Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL318658A true IL318658A (en) | 2025-03-01 |
Family
ID=82786438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL318658A IL318658A (en) | 2022-07-29 | 2023-07-31 | Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4561585A1 (en) |
| JP (1) | JP2025525092A (en) |
| KR (1) | KR20250047769A (en) |
| CN (1) | CN119855595A (en) |
| AU (1) | AU2023313374A1 (en) |
| CA (1) | CA3263498A1 (en) |
| IL (1) | IL318658A (en) |
| MX (1) | MX2025001127A (en) |
| WO (1) | WO2024023359A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119307451A (en) * | 2024-11-21 | 2025-01-14 | 中国医学科学院基础医学研究所 | An in vitro rat pinealocyte calcification model and its construction method |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4755612A (en) * | 1987-07-20 | 1988-07-05 | Merck & Co., Inc. | Intermediate compounds resulting from method for forming a dihydrogen-phosphate inositol |
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| JPH07507059A (en) | 1992-03-25 | 1995-08-03 | デポムド システムズ，インコーポレイテッド | Extended release oral drug dosage forms based on alkyl-substituted cellulose |
| AU3290397A (en) | 1996-06-10 | 1998-01-07 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| PT998271E (en) | 1997-06-06 | 2005-10-31 | Depomed Inc | FORMS OF ORAL DOSAGE OF DRUGS WITH GASTRIC RETENTION FOR THE CONTROLLED LIBERATION OF HIGHLY SOLUABLE DRUGS |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| EP1242057A2 (en) | 1999-11-02 | 2002-09-25 | DepoMed, Inc. | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
| PT1251832E (en) | 2000-02-04 | 2007-01-31 | Depomed Inc | Shell-and-core dosage form approaching zero-order drug release |
| US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| US6451808B1 (en) | 2000-10-17 | 2002-09-17 | Depomed, Inc. | Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists |
| US20030031711A1 (en) | 2001-05-29 | 2003-02-13 | Fara John W. | Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough |
| US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| EP1438027A1 (en) | 2001-10-25 | 2004-07-21 | DepoMed, Inc. | Methods of treatment using a gastric retained losartan dosage |
| CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
| ES2232302B1 (en) | 2003-11-07 | 2006-08-01 | Universitat De Les Illes Balears | MYO-INOSITOL HEXAFOSFATO FOR TOPICAL USE. |
| ES2288126B2 (en) | 2006-06-01 | 2009-07-06 | Universitat De Les Illes Balears | USE OF FITATE AS AN INHIBITING AGENT FOR THE DISSOLUTION OF CRYSTALS OF SALES CALCICAS FOR THE PREVENTION OR TREATMENT OF OSTEOPOROSIS. |
| ES2332636B1 (en) | 2008-08-06 | 2011-02-10 | Universitat De Les Illes Balears | COMPOSITION OF DIALYSIS LIQUID. |
| EP2579036A1 (en) | 2011-10-06 | 2013-04-10 | Laboratorios Sanifit, S.L. | Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200 |
| AU2016368547B2 (en) * | 2015-12-11 | 2021-11-18 | ETH Zürich | Inositol derivatives for use in pathological crystallization |
| WO2020074944A1 (en) * | 2018-10-11 | 2020-04-16 | Sanifit Therapeutics S.A. | Inositol phosphates for the treatment of ectopic calcification |
| EP4036097A1 (en) * | 2021-01-29 | 2022-08-03 | Sanifit Therapeutics S.A. | Ip4-4,6 substituted derivative compounds |
-
2023
- 2023-07-31 IL IL318658A patent/IL318658A/en unknown
- 2023-07-31 EP EP23750980.7A patent/EP4561585A1/en active Pending
- 2023-07-31 CN CN202380064713.1A patent/CN119855595A/en active Pending
- 2023-07-31 KR KR1020257006659A patent/KR20250047769A/en active Pending
- 2023-07-31 JP JP2025505392A patent/JP2025525092A/en active Pending
- 2023-07-31 CA CA3263498A patent/CA3263498A1/en active Pending
- 2023-07-31 AU AU2023313374A patent/AU2023313374A1/en active Pending
- 2023-07-31 WO PCT/EP2023/071128 patent/WO2024023359A1/en not_active Ceased
-
2025
- 2025-01-27 MX MX2025001127A patent/MX2025001127A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023313374A1 (en) | 2025-02-13 |
| EP4561585A1 (en) | 2025-06-04 |
| CN119855595A (en) | 2025-04-18 |
| CA3263498A1 (en) | 2024-02-01 |
| KR20250047769A (en) | 2025-04-04 |
| WO2024023359A1 (en) | 2024-02-01 |
| MX2025001127A (en) | 2025-06-02 |
| JP2025525092A (en) | 2025-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008147864A3 (en) | Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions | |
| NO20070247L (en) | Amino-5,5-diphenylimidazolone derivatives for inhibition of beta-secretase | |
| ME01493B (en) | Lndolidone derivatives for the treatment or prevention of fibrotic diseases | |
| IL290177A (en) | 1,2,4-oxadiazol-5-one derivatives for the treatment of cancer | |
| IL280475B1 (en) | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease | |
| SG11202012070YA (en) | Methods and compositions for preventing or treating tissue calcification | |
| ZA202307970B (en) | Compounds for use in the treatment and prevention of covid- 19 | |
| RS67141B1 (en) | A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria | |
| IL318658A (en) | Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification | |
| IL316433A (en) | 1.8 for the treatment of pain | |
| GB201918414D0 (en) | Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency | |
| HK40123408A (en) | Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification | |
| AP2005003294A0 (en) | Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome | |
| SG11202010177UA (en) | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms | |
| IL312885A (en) | Nitroxoline for use in the treatment or prevention of flexiform neurofibroma | |
| ZA202107513B (en) | Compounds and compositions comprising the same for treating hypertension or heart failure | |
| IL282718A (en) | Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity | |
| KR102276379B9 (en) | IF1 ATPase inhibitory factor 1 Composition for Preventing or Treating Bone Diseases Comprising IF1 | |
| GB2610895B (en) | Composition for use in the treatment and/or prevention of mycotoxic disease | |
| GB2595502B (en) | Compounds, compositions and methods for the treatment or prevention of hair loss | |
| GB202202541D0 (en) | Composition for use in the treatment and/or prevention of mycotoxic disease | |
| IL285733A (en) | Acyl-protein thioesterase inhibitor for the treatment and/or prevention of huntington's disease | |
| IL324190A (en) | Use of compounds in the prevention or treatment of radiation-induced brain injury | |
| GB202302121D0 (en) | Compounds for use in the treatment of schizophrenia | |
| IL170706A0 (en) | Use of atii antagonist for the treatment or prevention of metabolic syndrome |